Back to Search
Start Over
Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.
- Source :
- Clinical Infectious Diseases; 4/1/2016, Vol. 62 Issue 7, p951-953, 3p
- Publication Year :
- 2016
-
Abstract
- The article discusses the clinical and immunological effects of subsequent granulocyte colony-stimulating factor (G-CSF) and ruxolitinib therapy in a chronic mucocutaneous candidiasis (CMC) patient. It states that G-CSF lacks the immunological and clinical response. It mentions that ruxolitinib shows continuous amelioration of CMC over months.
Details
- Language :
- English
- ISSN :
- 10584838
- Volume :
- 62
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Clinical Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 113743586
- Full Text :
- https://doi.org/10.1093/cid/ciw020